Ï㽶ÊÓƵ

News

HIV-1 Ï㽶ÊÓƵ target site for the development of HIV drug or gene therapy

Published: 4 October 2019

Invention 14004

HIV-1 Ï㽶ÊÓƵ target site for the development of HIV drug or gene therapy

A highly conserved HIV-1 Ï㽶ÊÓƵ sequence that could be used as a target site for potential gene therapy treatments has been identified at Ï㽶ÊÓƵ.

Market Need

The current HIV treatment regimen of chemotherapy and antiretroviral therapy only suppresses the disease, requiring continued lifelong treatment. Directed gene therapy, on the other hand, is an approach that alters the genetic code of cells or viruses. One promising form of gene therapy, Ï㽶ÊÓƵ interference (Ï㽶ÊÓƵi), binds to a specific Ï㽶ÊÓƵ sequence in order to suppress that gene’s function. With the proper target site, short interfering Ï㽶ÊÓƵ (siÏ㽶ÊÓƵ) or short hairpin Ï㽶ÊÓƵ (shÏ㽶ÊÓƵ) treatment could either be combined with other drugs or as a stand-alone way of blocking entry to human cells. While only a few gene therapy products have been FDA approved, early HIV gene therapy products are joining hundreds of promising cancer and neurodegenerative disorder clinical studies.

Technology Summary

In this invention, the HIV-1 Ï㽶ÊÓƵ target site identified by the Gatignol Lab is highly conserved and easily accessible to Ï㽶ÊÓƵ molecules. For Ï㽶ÊÓƵi inhibitory targeting to be successful in HIV, the target sequence needs to be highly conserved across multiple HIV-1 strains. Ï㽶ÊÓƵi treatments would therefore be able to bind to a greater percentage of HIV strains as this region has a lower rate of mutation and is therefore more likely to be present in HIV+ individuals. Since this is a more highly conserved sequence than other patented sequences, the inventors are confident a useful treatment can be produced from this target site. The investigators have importantly shown that this target site is also capable of being used with combinatorial treatment strategies of antisense, siÏ㽶ÊÓƵ, and shÏ㽶ÊÓƵ, although ribozyme or aptamer accessibility has not been screened.

Advantages

  • Superior to many other patented sites in terms of gene conservation across HIV-1 strains, specificity, and accessibility to different small Ï㽶ÊÓƵ technologies
  • Can be used in drug or gene therapy to treat HIV infection using antisense Ï㽶ÊÓƵ, siÏ㽶ÊÓƵ, shÏ㽶ÊÓƵ
  • Higher conservation means a lower chance of mutation and presence in higher proportion of different HIV-1 strains

Patent Status

Issued US, filed CA

Ìý

Back to top